Abstract
EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma.
Original language | English |
---|---|
Pages (from-to) | 481-9 |
Number of pages | 9 |
Journal | The Lancet Oncology |
Volume | 14 |
Issue number | 6 |
DOIs | |
Publication status | Published - May 2013 |
Bibliographical note
Copyright © 2013 Elsevier Ltd. All rights reserved.Keywords
- Adenocarcinoma
- Aged
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
- Chi-Square Distribution
- Deoxycytidine
- Disease-Free Survival
- Early Termination of Clinical Trials
- Epirubicin
- Esophageal Neoplasms
- Female
- Fluorouracil
- Great Britain
- Humans
- Intention to Treat Analysis
- Kaplan-Meier Estimate
- Logistic Models
- Male
- Middle Aged
- Molecular Targeted Therapy
- Multivariate Analysis
- Odds Ratio
- Organoplatinum Compounds
- Proportional Hazards Models
- Protein Kinase Inhibitors
- Receptor, Epidermal Growth Factor
- Stomach Neoplasms
- Time Factors
- Treatment Outcome
- Tumor Markers, Biological